San Diego-based BioNano Genomics Inc., a genome-mapping device company, has raised $68.5 million in financing, according to a recent filing with the Securities and Exchange Commission.

The filing includes the $53 million Series C round announced late last year, led by Novartis Venture Fund and Legend Capital, along with a slew of repeat and strategic new investors.

The funds are intended to support commercialization of BioNano’s new genome-mapping platform, the Irys System.

BioNano officials said the proceeds would specifically go towards expansion of commercialization efforts, the development and launch of the next-generation system and the establishment of the company’s “diagnostic roadmap,” including readiness of a cytogenetics assay.

BioNano declined to discuss the extra $15 million included in the filing.